UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) June 2, 2022 ( May 26, 2022)
Teladoc Health, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | | 001-37477 | | 04-3705970 |
(State or other jurisdiction
of incorporation) | | (Commission
File Number) | | (I.R.S. Employer
Identification No.) |
2 Manhattanville Road, Suite 203
Purchase, New York | | 10577 |
| (Address of Principal Executive Offices) | | (Zip Code) |
(203) 635-2002
Registrant’s telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | | Trading
Symbol(s) | | Name of each exchange on which
registered |
| Common Stock, par value $0.001 per share | | TDOC | | The New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On May 26, 2022, at the 2022 Annual Meeting of Stockholders (the “Annual Meeting”) of Teladoc Health, Inc. (the “Company”), the stockholders of the Company approved an amendment to the Company’s Certificate of Incorporation (the “Certificate Amendment”) that enables one or more holders of at least 15% Net Long Ownership (as defined in the Company’s Sixth Amended and Restated Bylaws) in voting power of the Company’s capital stock and who comply with the other applicable procedures and other requirements set forth in the Sixth Amended and Restated Bylaws to call a special meeting of the Company’s stockholders. Following the Annual Meeting, on June 1, 2022, the Company filed its Seventh Amended and Restated Certificate of Incorporation, reflecting the Certificate Amendment, with the Secretary of State of the State of Delaware, at which time the Seventh Amended and Restated Certificate of Incorporation became effective.
On May 31, 2022, the Board of Directors of the Company approved a corresponding amendment and restatement of the Company’s Bylaws (the “Sixth Amended and Restated Bylaws”) to implement the Certificate Amendment, which Sixth Amended and Restated Bylaws were conditioned upon the effectiveness of the filing of the Seventh Amended and Restated Certificate of Incorporation. In particular, the Sixth Amended and Restated Bylaws provide that “Net Long Ownership,” when used to describe the nature of a stockholder’s ownership of the Company’s capital stock, means the capital stock of the Company that such stockholder, or a beneficial owner, would be deemed to own pursuant to the definition of “net long position” set forth in Rule 14e-4 under the Exchange Act of 1934, as amended, and the rules and regulations thereunder, excluding (i) any capital stock as to which such stockholder or beneficial owner does not then have the right to vote or direct the vote, and (ii) any capital stock to which such stockholder or beneficial owner (or any affiliate or associate of such stockholder or beneficial owner) had directly or indirectly entered into, and not yet terminated, certain short interests. The Sixth Amended and Restated Bylaws also set forth certain other requirements that the Board of Directors believes are appropriate to ensure an orderly and informed meeting process and to avoid duplicative or unnecessary special meetings, including requirements for proof of Net Long Ownership and other information that are similar to those in the Company’s advance notice bylaws, certain timing requirements and other provisions. The Sixth Amended and Restated Bylaws also specify the procedures for stockholder requested meetings and certain other clarifying, administrative, conforming, ministerial and related revisions related to, among other things, director nominations and notice provisions. The Sixth Amended and Restated Bylaws became effective upon the effectiveness of the filing of the Seventh Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware.
The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the full text of the Seventh Amended and Restated Certificate of Incorporation and the Sixth Amended and Restated Bylaws, copies of which are filed as Exhibits 3.1 and 3.2 to this Current Report on Form 8-K and are incorporated herein by reference.
Item 5.07. Submission of Matters to a Vote of Security Holders.
The Annual Meeting was held on May 26, 2022. The Company previously filed with the Securities and Exchange Commission a definitive proxy statement and related materials pertaining to the Annual Meeting, which describe in detail each of the four proposals submitted to stockholders at the Annual Meeting. The final results for the votes regarding each proposal are set forth below.
Proposal 1 — Election of Directors
The stockholders of the Company elected each of the following director nominees proposed by the Company’s Board of Directors to serve until the 2023 Annual Meeting of Stockholders of the Company and until their respective successors have been duly elected and qualified. The voting results for each director nominee are set forth below.
| Name | | For | | | Against | | | Abstentions | | | Broker Non-
Votes | |
| Karen L. Daniel | | | 87,006,491 | | | | 495,212 | | | | 88,759 | | | | 28,950,099 | |
| Sandra L. Fenwick | | | 86,600,404 | | | | 899,854 | | | | 90,204 | | | | 28,950,099 | |
| William H. Frist, M.D. | | | 85,510,839 | | | | 1,996,663 | | | | 82,960 | | | | 28,950,099 | |
| Jason Gorevic | | | 86,939,178 | | | | 557,356 | | | | 93,928 | | | | 28,950,099 | |
| Catherine A. Jacobson | | | 87,012,070 | | | | 483,624 | | | | 94,768 | | | | 28,950,099 | |
| Thomas G. McKinley | | | 83,533,746 | | | | 3,954,946 | | | | 101,770 | | | | 28,950,099 | |
| Kenneth H. Paulus | | | 86,180,125 | | | | 1,309,263 | | | | 101,074 | | | | 28,950,099 | |
| David L. Shedlarz | | | 85,325,480 | | | | 2,161,360 | | | | 103,622 | | | | 28,950,099 | |
| Mark Douglas Smith, M.D., MBA | | | 86,580,563 | | | | 918,131 | | | | 91,768 | | | | 28,950,099 | |
| David B. Snow, Jr. | | | 85,007,672 | | | | 2,481,984 | | | | 100,806 | | | | 28,950,099 | |
Proposal 2 — Advisory Vote Approving the Compensation of the Company’s Named Executive Officers
The stockholders of the Company approved, on an advisory basis, the compensation paid to the Company’s named executive officers. The voting results are set forth below.
| For | | | Against | | | Abstentions | | | Broker Non-Votes | |
| | 80,030,674 | | | | 7,339,906 | | | | 219,882 | | | | 28,950,099 | |
Proposal 3 — Ratifying the Appointment of the Independent Registered Public Accounting Firm
The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The voting results are set forth below.
| For | | | Against | | | Abstentions | | | Broker Non-Votes |
| | 115,926,691 | | | | 384,899 | | | | 228,971 | | | N/A |
Proposal 4 — Approving an Amendment to the Company’s Certificate of Incorporation to Permit Stockholders to Call Special Meetings
The stockholders of the Company approved an amendment to the Company’s Certificate of Incorporation to permit holders of at least 15% net long ownership in voting power of the Company’s outstanding capital stock to call special meetings. The voting results are set forth below.
| For | | | Against | | | Abstentions | | | Broker Non-Votes | |
| | 87,128,040 | | | | 342,730 | | | | 119,692 | | | | 28,950,099 | |
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: June 2, 2022 | TELADOC HEALTH, INC. |
| | | |
| | By: | /s/ Adam C. Vandervoort |
| | Name: | Adam C. Vandervoort |
| | Title: | Chief Legal Officer and Secretary |
